CDKN1A and cancer: 4-hydroxytamoxifen (OHT, an active metabolite of tamoxifen), alpelisib, the p21 (CDKN1A) inhibitor UC2288 [86], and the STAT3 inhibitor C188-9 [87] showed a wide TW, and hence, more selectivity for cancer cells and less toxicity as monotherapies (Fig. S2).